deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT00500812

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Spinal Cord Injury
Interventions Cethrin
Updated 7 times since 2017 Last updated: Mar 15, 2016 Started: Feb 28, 2005 Primary completion: Dec 31, 2008 Completion: Feb 28, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Spinal Cord Injury, this trial is completed. The trial is conducted by Vertex Pharmaceuticals Incorporated and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vertex Pharmaceuticals Incorporated
Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations